NY A07465 | 2023-2024 | General Assembly
Status
Spectrum: Partisan Bill (Democrat 30-1)
Status: Introduced on May 24 2023 - 25% progression
Action: 2024-01-03 - referred to health
Pending: Assembly Health Committee
Text: Latest bill text (Introduced) [HTML]
Status: Introduced on May 24 2023 - 25% progression
Action: 2024-01-03 - referred to health
Pending: Assembly Health Committee
Text: Latest bill text (Introduced) [HTML]
Summary
Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filer's product for any period of time.
Title
Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filer's product for any period of time.
Sponsors
History
Date | Chamber | Action |
---|---|---|
2024-01-03 | Assembly | referred to health |
2023-05-24 | Assembly | referred to health |
Same As/Similar To
S04513 (Same As) 2024-05-15 - REPORTED AND COMMITTED TO FINANCE